Nucleo reported Q3-2026 revenue of 10 million euros, up 26% year over year. Free cash flow was approximately negative 24 million euro, and the company ended the quarter with 233 million euro of cash and equivalents. It expects cash burn to increase over the coming quarters as MOX facility spending steps up.
NWCL · newcleo plc · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
newcleo plc reported third-quarter 2026 revenue from products and services of approximately €10.0 million, up approximately 26% from a year earlier. Cash and cash equivalents stood at €233.4 million as of September 30, 2026.
newcleo plc and Curio Legacy Ventures, Inc. agreed to collaborate on supplying recycled used nuclear fuel and transuranic materials for a planned U.S. MOX fuel manufacturing facility, including commercial-arrangement evaluation and recycling R&D.
newcleo plc will release operational updates and preliminary financial information for the third quarter ended September 30, 2026, before the U.S. market opens on Wednesday, November 18, 2026, followed by a conference call and webcast.
newcleo plc completed its acquisition of Bonifait Pesage, a French maker of nuclear-grade weighing equipment, valuing it at €1.8 million. Bonifait Pesage reported revenue of approximately €2.1 million in 2025; consideration combined cash and newcleo shares.
newcleo inaugurated FASTER, a €10 million nuclear fuel engineering and testing center in Chusclan, France, with Seven operating test facilities supporting MOX manufacturing development. Its proposed Aube facility received an overall satisfactory safety evaluation from ASNR in July 2026.
newcleo plc shareholders approved the Prepaid Share Forward Confirmation dated September 11, 2026, authorizing an off-market purchase of up to 7,000,000 ordinary shares; the ordinary resolution received 99.98% of votes cast.
newcleo plc registers up to 217,834,936 ordinary shares and 9,146,717 ordinary shares underlying warrants for resale or issuance. The company may receive private-warrant exercise proceeds if exercised for cash, but no cash proceeds from share resales or NextChem warrant exercises.
newcleo completed its business combination with NewHold Investment Corp III on September 21, 2026, generating approximately $247 million, and installed PRECURSOR’s main vessel and turbine. First Half 2026 revenue was approximately €19.4 million and net loss approximately €82.0 million.
newcleo announced that William D. Magwood, IV is anticipated to join its Board of Directors as Vice-Chairman, effective January 1, 2027, bringing experience in nuclear regulation, policy and international licensing.
newcleo plc completed its business combination with NewHold Investment Corp III on September 21, 2026; its ordinary shares and public warrants began trading on Nasdaq Global Market on September 22, 2026 under “NWCL” and “NWCLW.”
newcleo plc completed its combination with NewHold Investment Corp III, raising approximately $247 million in gross proceeds and valuing the company at approximately $2.4 billion pre-money. Nasdaq trading was scheduled to begin September 22, 2026 under “NWCL” and “NWCLW”.